L3VLUP
ProSign in

BNTX · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BNTXAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BNTX
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterBNTXAMGN
Q3 20204 holders, $504m16 holders, $16.3bn
Q4 20203 holders, $142m19 holders, $14.0bn
Q1 20214 holders, $993m16 holders, $14.5bn
Q2 202110 holders, $3.9bn23 holders, $13.8bn
Q3 202112 holders, $4.2bn24 holders, $11.6bn
Q4 20219 holders, $3.1bn21 holders, $10.4bn
Q1 202210 holders, $1.9bn23 holders, $9.9bn
Q2 202211 holders, $1.8bn28 holders, $9.7bn
Q3 20228 holders, $1.8bn21 holders, $7.9bn
Q4 202213 holders, $2.3bn24 holders, $9.3bn
Q1 20238 holders, $1.6bn22 holders, $8.4bn
Q2 202310 holders, $1.2bn26 holders, $7.4bn
Q3 20239 holders, $1.2bn26 holders, $8.7bn
Q4 20239 holders, $1.1bn24 holders, $8.4bn
Q1 20247 holders, $975m25 holders, $6.7bn
Q2 20249 holders, $877m20 holders, $8.0bn
Q3 202410 holders, $2.0bn21 holders, $8.8bn
Q4 20248 holders, $2.0bn20 holders, $8.2bn
Q1 20259 holders, $1.6bn25 holders, $12.0bn
Q2 20256 holders, $1.9bn20 holders, $10.2bn
Q3 20254 holders, $1.7bn17 holders, $10.4bn
Q4 20258 holders, $1.2bn19 holders, $18.0bn
Q1 20266 holders, $528m15 holders, $21.4bn
Q2 20269 holders, $1.3bn23 holders, $24.9bn
BNTX

Biontech Se

Holders
10
Reported value
$2.0bn
Buyers
7
Sellers
3

Breadth +4 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
21
Reported value
$8.8bn
Buyers
16
Sellers
5

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BNTX (7)

Baillie Gifford & Co, Discovery Capital Management LLC, Hudson Bay Capital Management LP, Point72 Asset Management LP, Squarepoint Ops LLC, Viking Global Investors LP, Voloridge Investment Management LLC

Only AMGN (18)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →